Now showing items 1-1 of 1
Melanoma drug discovery: Prioritization of candidate melanoma driver mutations in the ErbB4 receptor tyrosine kinase gene and identification of novel molecules that disrupt ErbB4 signaling
BRAF V600E mutations are found in roughly 50% of metastatic melanomas. While these tumors typically initially respond to BRAF and/or MEK inhibitors, they frequently develop resistance to BRAF and/or MEK inhibition. ...